Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News
Financial Results · Q3 2026

Reviva Pharmaceuticals Holdings Q3 2026 Results: Net Loss of $2.3M, Loss Narrows

Reviva Pharmaceuticals reported a net loss of $7.9 million for the nine months ended September 30, 2026, a significant reduction from the $16.5 million loss in the prior year period. The company strengthened its liquidity through public and ATM offerings, ending the quarter with $17.5 million in cash and cash equivalents.

Q3 2026 at a glance · $ million
MetricQ3 2026Q3 2025
Profit before tax-2.3-4.0
Net income-2.3-4.0
EPS (diluted, $ a share)$-0.17$-1.09

A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.

Source

10-Q filed with the SEC, OTC: RVPH. Figures from the filing's XBRL data; summary written with AI assistance from the filing.

Read the filing ↗

Reviva Pharmaceuticals Holdings, Inc.: key numbers

Share price
$0.3000Close, Nov 16
Market cap
$3.93M
Shares outstanding
13.11MLatest SEC cover page
Sector
Life Sciences
Industry
Pharmaceutical PreparationsSIC 2834

Today's reference numbers, updated daily. Not a valuation or a recommendation.

More from Reviva Pharmaceuticals Holdings, Inc.

All →
6:05 AM ET 8-K
Financial Results

Reviva Pharmaceuticals Holdings Financial Results

Reviva Pharmaceuticals reported a net loss of $2.3 million for the third quarter of 2026, an improvement from a $4.0 million loss in the prior year period. The company is awaiting FDA feedback in Q4 2026 regarding a new formulation of brilaroxazine for its Phase 3 RECOVER-2 trial in schizophrenia. Reviva also noted it has filed a new composition of matter patent application that could extend protection for brilaroxazine through 2046.

Term
Q3 2026

“Our near-term focus is obtaining Food and Drug Administration (FDA) feedback on the proposed use of a new formulation of brilaroxazine and preparing for the next stages of clinical development while managing our capital resources carefully.”

Laxminarayan Bhat, Founder, President, and CEO of Reviva

“We remain focused on disciplined execution as we advance brilaroxazine as a potentially differentiated treatment option for patients with schizophrenia.”

Laxminarayan Bhat, Founder, President, and CEO of Reviva

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.